Modeling Pharmaceutical Powder-Flow Performance Using Particle-Size Distribution Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Modeling Pharmaceutical Powder-Flow Performance Using Particle-Size Distribution Data
The authors present a simple and material-sparing approach for estimating the powder-flow performance of previously uncharacterized single-component bulk powders when only particle-size distribution data are available.


Pharmaceutical Technology
Volume 33, Issue 3, pp. 126-134

Conclusion

Models have been developed for predicting relative powder-flow performance using PSD data. The PLS model, which used D10, D50, D90, and D[4,3] as input parameters, is suitable for predicting the FFC value for APIs and excipients and may also be appropriate for predicting PSD influences on other materials (e.g., active blends and active granulations). This empirical tool leverages a material and resource-sparing approach to the powder-flow performance characterization. In addition, the tool can be particularly useful during prototype drug-product design, especially with regard to risk assessments when little is known about the flow performance of a new API or excipient.

Acknowledgment

The authors would like to thank Bruno Hancock for reviewing this work and providing technical guidance.

Matthew P. Mullarney* and Norma Leyva are senior scientists at Pfizer, Inc., Eastern Point Rd., Groton, CT 06340, tel. 860.715.4139,
.

*To whom all correspondence should be addressed.

Submitted: June 16, 2008. Accepted: July 8, 2008.




What would you do differently? Submit your comments about this paper in the space below.

References

1. E.N. Hiestand, "Mechanics and Physical Principles for Powders and Compacts" (SSCI Inc., West Lafayette, IN, 2002), p 110.

2. J. Staniforth, "Powder Flow," in Pharmaceutics: The Science of Dosage Form Design, M.E. Aulton, Ed. (Churchill Livingstone, Edinburgh, UK, 2002) pp. 197–210.

3. G.E. Amidon and M.E. Houghton, "Powder Flow Testing in Preformulation and Formulation Development," Pharma. Manuf., 2 (7) 21–31 (1985).

4. A.W. Jenike, "Storage and Flow of Solids," in Utah Engineering Experiment Station Bulletin 123, 16th ed., (University of Utah, Salt Lake City, UT, 1964).

5. T. Kohler and H. Schubert, "Influence of Particle Size Distribution on the Flow Behavior of Fine Powders," Part. Syst. Charact. 8 (1–4), 101–104 (1991).

6. F. Podczeck and Y. Miah, "The Influence of Particle Size and Shape on the Angle of Internal Friction and the Flow Factor of Unlubricated and Lubricated Powders," Int. J. Pharm. 144 (2) 187–194 (1996).

7. L. Breiman et al., "Classification and Regression Trees" (Chapman & Hall/CRC, Boca Raton, FL, 1984).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
25%
To select processes for both new and legacy products
20%
Do not use QbD
23%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here